Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Tumor necrosis factor primes and metal particles activate the NLRP3 inflammasome in human primary macrophages.

Jämsen E, Pajarinen J, Kouri VP, Rahikkala A, Goodman SB, Manninen M, Nordström DC, Eklund KK, Nurmi K.

Acta Biomater. 2020 Mar 17. pii: S1742-7061(20)30149-5. doi: 10.1016/j.actbio.2020.03.017. [Epub ahead of print]

PMID:
32194260
2.

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Gale SL, John M, Luder Y, Courvoisier DS, Gabay C.

Semin Arthritis Rheum. 2020 Feb;50(1):17-24. doi: 10.1016/j.semarthrit.2019.06.020. Epub 2019 Jun 28.

3.

Haploinsufficiency of A20 impairs protein-protein interactome and leads into caspase-8-dependent enhancement of NLRP3 inflammasome activation.

Rajamäki K, Keskitalo S, Seppänen M, Kuismin O, Vähäsalo P, Trotta L, Väänänen A, Glumoff V, Keskitalo P, Kaarteenaho R, Jartti A, Hautala N, Jackson P, Nordström DC, Saarela J, Hautala T, Eklund KK, Varjosalo M.

RMD Open. 2018 Oct 17;4(2):e000740. doi: 10.1136/rmdopen-2018-000740. eCollection 2018.

4.

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.

PMID:
29730637
5.

Activation of plasmacytoid dendritic cells by apoptotic particles - mechanism for the loss of immunological tolerance in Sjögren's syndrome.

Ainola M, Porola P, Takakubo Y, Przybyla B, Kouri VP, Tolvanen TA, Hänninen A, Nordström DC.

Clin Exp Immunol. 2018 Mar;191(3):301-310. doi: 10.1111/cei.13077. Epub 2017 Nov 28.

6.

Infection and apoptosis associated with inflammation in periodontitis: An immunohistologic study.

Listyarifah D, Al-Samadi A, Salem A, Syaify A, Salo T, Tervahartiala T, Grenier D, Nordström DC, Sorsa T, Ainola M.

Oral Dis. 2017 Nov;23(8):1144-1154. doi: 10.1111/odi.12711. Epub 2017 Aug 7.

PMID:
28686335
7.

Toll-like receptors and their soluble forms differ in the knee and thumb basal osteoarthritic joints.

Barreto G, Sandelin J, Salem A, Nordström DC, Waris E.

Acta Orthop. 2017 Jun;88(3):326-333. doi: 10.1080/17453674.2017.1281058. Epub 2017 Jan 17.

8.

Correlations between macrophage polarizing cytokines, inflammatory mediators, osteoclast activity, and toll-like receptors in tissues around aseptically loosened hip implants.

Jämsen E, Kouri VP, Ainola M, Goodman SB, Nordström DC, Eklund KK, Pajarinen J.

J Biomed Mater Res A. 2017 Feb;105(2):454-463. doi: 10.1002/jbm.a.35913. Epub 2016 Oct 31.

PMID:
27669374
9.

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF.

Arthritis Res Ther. 2016 Jun 20;18(1):144. No abstract available.

10.

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF; Rheumatic Diseases Portuguese Register.

Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z. Erratum in: Arthritis Res Ther. 2016;18(1):144.

11.

Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis.

Barreto G, Soininen A, Ylinen P, Sandelin J, Konttinen YT, Nordström DC, Eklund KK.

Arthritis Res Ther. 2015 Dec 24;17:379. doi: 10.1186/s13075-015-0902-0.

12.

Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.

Heinonen AV, Aaltonen KJ, Joensuu JT, Lähteenmäki JP, Pertovaara MI, Romu MK, Hirvonen HE, Similä AK, Blom ML, Nordström DC.

J Rheumatol. 2015 Dec;42(12):2339-46. doi: 10.3899/jrheum.150389. Epub 2015 Oct 15.

PMID:
26472421
13.

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.

Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, Canhao H, Chatzidionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PL, van Vollenhoven R, Kvien TK.

Ann Rheum Dis. 2016 Jul;75(7):1336-42. doi: 10.1136/annrheumdis-2015-207760. Epub 2015 Sep 15.

14.

Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.

Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordström DC, Canhão H, Tomšič M, van Vollenhoven R, Gabay C.

Rheumatology (Oxford). 2016 Feb;55(2):230-6. doi: 10.1093/rheumatology/kev297. Epub 2015 Aug 27.

PMID:
26316581
15.

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.

Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PLCM, van de Laar MAFJ, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL.

Rheumatology (Oxford). 2015 Jun;54(6):1074-1079. doi: 10.1093/rheumatology/keu446. Epub 2014 Nov 27.

PMID:
25433042
16.

Activation of histamine H4 receptor inhibits TNFα/IMD-0354-induced apoptosis in human salivary NS-SV-AC cells.

Stegajev V, Kouri VP, Salem A, Rozov S, Stark H, Nordström DC, Konttinen YT.

Apoptosis. 2014 Dec;19(12):1702-11. doi: 10.1007/s10495-014-1036-6.

PMID:
25239604
17.

Toll-like receptors in human chondrocytes and osteoarthritic cartilage.

Sillat T, Barreto G, Clarijs P, Soininen A, Ainola M, Pajarinen J, Korhonen M, Konttinen YT, Sakalyte R, Hukkanen M, Ylinen P, Nordström DC.

Acta Orthop. 2013 Dec;84(6):585-92. doi: 10.3109/17453674.2013.854666. Epub 2013 Nov 18.

18.

Histamine transport and metabolism are deranged in salivary glands in Sjogren's syndrome.

Stegaev V, Nies AT, Porola P, Mieliauskaite D, Sánchez-Jiménez F, Urdiales JL, Sillat T, Schwelberger HG, Chazot PL, Katebe M, Mackiewicz Z, Konttinen YT, Nordström DC.

Rheumatology (Oxford). 2013 Sep;52(9):1599-608. doi: 10.1093/rheumatology/ket188. Epub 2013 May 24.

PMID:
23709238
19.

Do changing toll-like receptor profiles in different layers and grades of osteoarthritis cartilage reflect disease severity?

Barreto G, Sillat T, Soininen A, Ylinen P, Salem A, Konttinen YT, Al-Samadi A, Nordström DC.

J Rheumatol. 2013 May;40(5):695-702. doi: 10.3899/jrheum.121159. Epub 2013 Mar 15.

PMID:
23504385
20.

Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.

Aaltonen KJ, Virkki LM, Jämsen E, Sokka T, Konttinen YT, Peltomaa R, Tuompo R, Yli-Kerttula T, Kortelainen S, Ahokas-Tuohinto P, Blom M, Nordström DC.

Semin Arthritis Rheum. 2013 Aug;43(1):55-62. doi: 10.1016/j.semarthrit.2013.01.002. Epub 2013 Mar 5.

PMID:
23481417
21.

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.

PLoS One. 2012;7(1):e30275. doi: 10.1371/journal.pone.0030275. Epub 2012 Jan 17. Review.

22.

Osteoarthritis as an autoinflammatory disease caused by chondrocyte-mediated inflammatory responses.

Konttinen YT, Sillat T, Barreto G, Ainola M, Nordström DC.

Arthritis Rheum. 2012 Mar;64(3):613-6. doi: 10.1002/art.33451. No abstract available.

23.

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C.

Ann Rheum Dis. 2012 Mar;71(3):374-7. doi: 10.1136/annrheumdis-2011-200003. Epub 2011 Oct 4.

PMID:
21972242
24.

Failure of oral DHEA treatment to increase local salivary androgen outputs of female patients with Sjögren's syndrome.

Porola P, Straub RH, Virkki LM, Konttinen YT, Nordström DC.

Scand J Rheumatol. 2011;40(5):387-90. doi: 10.3109/03009742.2011.580000. Epub 2011 Aug 31.

PMID:
21877998
25.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, Koivuniemi R, Yli-Kerttula U, Mali M, Sihvonen S, Krogerus ML, Jukka E, Nyrhinen S, Konttinen YT, Nordström DC.

Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7.

PMID:
21644062
26.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
27.

Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years.

Virkki LM, Sumathikutty BC, Aarnio M, Valleala H, Heikkilä R, Kauppi M, Karstila K, Pirilä L, Ekman P, Salomaa S, Romu M, Seppälä J, Niinisalo H, Konttinen YT, Nordström DC.

J Rheumatol. 2010 Nov;37(11):2362-8. doi: 10.3899/jrheum.091477. Epub 2010 Aug 17.

PMID:
20716655
28.

[Central nervous system vasculitis].

Hietaharju A, Pettersson T, Nordström DC, Kähärä V, Leivo I, Hernesniemi J, Konttinen YT.

Duodecim. 2009;125(1):27-37. Finnish.

PMID:
19341024
29.

Roadmap to vasculitis.

Konttinen YT, Rotar Z, Pettersson T, Nordström DC, Bacon P, Petersen J.

Acta Reumatol Port. 2006 Jan-Mar;31(1):15-36. Review.

30.

Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events.

Konttinen L, Honkanen V, Uotila T, Pöllänen J, Waahtera M, Romu M, Puolakka K, Vasala M, Karjalainen A, Luukkainen R, Nordström DC; ROB-FIN study group.

Rheumatol Int. 2006 Aug;26(10):916-22. Epub 2006 Jan 10.

PMID:
16402217
31.

Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.

Nordström DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, Ilva K, Kaipiainen-Seppänen O, Malmi T, Ylä-Kerttula T, Honkanen V.

Rheumatol Int. 2006 Jun;26(8):741-8. Epub 2005 Oct 5.

PMID:
16205925
32.

Acute pseudogout in a patient with treated acromegaly.

Nordström DC, Aarnio M, Laasonen L.

Scand J Rheumatol. 2004;33(6):443-5. No abstract available.

PMID:
15794209
33.

The protein kinase C system in focal adenitis of the lacrimal gland in the non-obese diabetic mouse model for Sjögren's syndrome.

Tensing EK, Törnwall J, Hukkanen M, Nordström DC, Konttinen YT.

Acta Ophthalmol Scand. 2004 Oct;82(5):569-73.

34.

[Clinical picture and treatment of osteoarthritis].

Konttinen YT, Lindroos L, Ruuttila P, Lähdeoja T, Lassus J, Nordström DC, Santavirta S.

Duodecim. 2003;119(16):1537-44. Review. Finnish. No abstract available.

PMID:
14535026
35.

Salivary gland scintigraphy in Sjögren's syndrome and patients with sicca symptoms but without Sjögren's syndrome: the psychological profiles and predictors for salivary gland dysfunction.

Tensing EK, Nordström DC, Solovieva S, Schauman KO, Sippo-Tujunen I, Helve T, Natah S, Ma J, Li TF, Konttinen YT.

Ann Rheum Dis. 2003 Oct;62(10):964-8.

36.

[New drug treatments for rheumatoid arthritis].

Nordström DC, Konttinen YT.

Duodecim. 2000;116(11):1221-5. Review. Finnish. No abstract available.

PMID:
11989008
37.

Fatigue and health profile in sicca syndrome of Sjögren's and non-Sjögren's syndrome origin.

Tensing EK, Solovieva SA, Tervahartiala T, Nordström DC, Laine M, Niissalo S, Konttinen YT.

Clin Exp Rheumatol. 2001 May-Jun;19(3):313-6.

PMID:
11407086
38.

Immune responses to osteoarticular allografts of the knee--cytokine studies.

Nordström DC, Santavirta S, Aho A, Heikkilä J, Teppo AM, Konttinen YT.

Arch Orthop Trauma Surg. 1999;119(3-4):195-8.

PMID:
10392518
39.

Gly-X-Y repeat sequences in the treatment of active rheumatoid arthritis.

Arborelius M Jr, Konttinen YT, Nordström DC, Solovieva SA.

Rheumatol Int. 1999;18(4):129-35.

PMID:
10220832
40.

Is one year early, or too late? Comment on the article by Tak et al.

Konttinen YT, Nordström DC, Santavirta S, Bergroth V.

Arthritis Rheum. 1997 Oct;40(10):1912-4. No abstract available.

PMID:
9336439
41.

Reactive arthritis, diagnosis and treatment: a review.

Nordstrom DC.

Acta Orthop Scand. 1996 Apr;67(2):196-201. Review.

PMID:
8623582
42.

In- and out-patient rehabilitation in rheumatoid arthritis. A controlled, open, longitudinal, cost-effectiveness study.

Nordström DC, Konttinen YT, Solovieva S, Friman C, Santavirta S.

Scand J Rheumatol. 1996;25(4):200-6.

PMID:
8792796
43.

Alpha-linolenic acid in the treatment of rheumatoid arthritis. A double-blind, placebo-controlled and randomized study: flaxseed vs. safflower seed.

Nordström DC, Honkanen VE, Nasu Y, Antila E, Friman C, Konttinen YT.

Rheumatol Int. 1995;14(6):231-4.

PMID:
7597378
44.

Granzyme A-immunoreactive cells in synovial fluid in reactive and rheumatoid arthritis.

Nordström DC, Konttinen YT, Sorsa T, Nykanen P, Pettersson T, Santavirta S, Tschopp J.

Clin Rheumatol. 1992 Dec;11(4):529-32.

PMID:
1283120
45.

Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus.

Metsärinne KP, Nordström DC, Konttinen YT, Teppo AM, Fyhrquist FY.

Rheumatol Int. 1992;12(3):93-6.

PMID:
1384103
46.

Effect of interleukin-1 on hyaluronate synthesis by synovial fibroblastic cells.

Konttinen YT, Saari H, Nordström DC.

Clin Rheumatol. 1991 Jun;10(2):151-4.

PMID:
1914415

Supplemental Content

Loading ...
Support Center